moxifloxacin has been researched along with valacyclovir in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (valacyclovir) | Trials (valacyclovir) | Recent Studies (post-2010) (valacyclovir) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,237 | 221 | 522 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, A; Jabbour, S; Shekhawat, NS; Woreta, FA | 1 |
| Arya, SK; Goel, I; Jha, UP; Nayyar, S; Rehman, O | 1 |
1 review(s) available for moxifloxacin and valacyclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for moxifloxacin and valacyclovir
| Article | Year |
|---|---|
Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Erythromycin; Eye Infections, Viral; Female; Herpes Zoster Ophthalmicus; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunization, Secondary; Latent Infection; Moxifloxacin; Vaccination; Valacyclovir; Virus Activation; Visual Acuity | 2021 |
Herpes Zoster Ophthalmicus After COVID-19 Vaccination: Chance Occurrence or More?
Topics: Acyclovir; Administration, Ophthalmic; Administration, Oral; Adult; Anti-Bacterial Agents; Antiviral Agents; ChAdOx1 nCoV-19; Conjunctivitis, Viral; COVID-19; Drug Therapy, Combination; Herpes Zoster Ophthalmicus; Humans; Male; Moxifloxacin; SARS-CoV-2; Vaccination; Valacyclovir; Visual Acuity | 2022 |